These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 2127351)

  • 1. Comparative in vitro activities of sparfloxacin (CI-978; AT-4140) and other antimicrobial agents against staphylococci, enterococci, and respiratory tract pathogens.
    Simor AE; Fuller SA; Low DE
    Antimicrob Agents Chemother; 1990 Nov; 34(11):2283-6. PubMed ID: 2127351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. SPAR Study Group.
    Ballow CH; Jones RN; Johnson DM; Deinhart JA; Schentag JJ
    Diagn Microbiol Infect Dis; 1997 Nov; 29(3):173-86. PubMed ID: 9401810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitivity to sparfloxacin and other antibiotics, of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis strains isolated from adult patients with community-acquired lower respiratory tract infections: a European multicentre study. SPAR Study Group. Surveillance Programme of Antibiotic Resistance.
    Richard MP; Aguado AG; Mattina R; Marre R
    J Antimicrob Chemother; 1998 Feb; 41(2):207-14. PubMed ID: 9533462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis.
    Jones RN; Ballow CH; Schentag JJ; Johnson DM; Deinhart JA
    Diagn Microbiol Infect Dis; 1998 May; 31(1):313-25. PubMed ID: 9597392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis.
    Davies TA; Kelly LM; Hoellman DB; Ednie LM; Clark CL; Bajaksouzian S; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2000 Mar; 44(3):633-9. PubMed ID: 10681330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BAY 12-8039, a novel fluoroquinolone. Activity against important respiratory tract pathogens.
    Biedenbach DJ; Barrett MS; Croco MA; Jones RN
    Diagn Microbiol Infect Dis; 1998 Sep; 32(1):45-50. PubMed ID: 9791757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of sparfloxacin (AT-4140 and CI-978), a new quinolone antimicrobial agent, against Haemophilus and gram-positive cocci.
    Rudrik JT; Ferrigno SR; Gee SL
    Diagn Microbiol Infect Dis; 1991; 14(4):355-60. PubMed ID: 1889186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moxifloxacin sensitivity of respiratory pathogens in the United Kingdom.
    Dorai-John T; Thomson CJ; Amyes SG
    J Chemother; 2002 Feb; 14(1):19-24. PubMed ID: 11892894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [National multicenter study of the in vitro activity of moxifloxacin against respiratory tract pathogens. Spanish Study Group on Moxifloxacin].
    Loza E; Morosini M; Negri MC; Almaraz F; Cantón R; Baquero F
    Rev Esp Quimioter; 2000 Mar; 13(1):37-43. PubMed ID: 10855023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of the novel ketolide HMR 3647 and comparative oral antibiotics against Canadian respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
    Hoban DJ; Zhanel GG; Karlowsky JA
    Diagn Microbiol Infect Dis; 1999 Sep; 35(1):37-44. PubMed ID: 10529880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
    Brueggemann AB; Kugler KC; Doern GV
    Antimicrob Agents Chemother; 1997 Jul; 41(7):1594-7. PubMed ID: 9210692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents.
    Blondeau JM; Vaughan D; Laskowski R; Borsos S;
    Int J Antimicrob Agents; 2001 Jun; 17(6):457-64. PubMed ID: 11397615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens.
    Souli M; Wennersten CB; Eliopoulos GM
    Int J Antimicrob Agents; 1998 Apr; 10(1):23-30. PubMed ID: 9624540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative in vitro activity of cefdinir (CI-983; FK-482) against staphylococci, gram-negative bacilli and respiratory tract pathogens.
    Scriver SR; Willey BM; Low DE; Simor AE
    Eur J Clin Microbiol Infect Dis; 1992 Jul; 11(7):646-52. PubMed ID: 1396778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative antimicrobial activity of the new macrolide flurithromycin against respiratory pathogens.
    Nord CE; Lindmark A; Persson I
    Eur J Clin Microbiol Infect Dis; 1988 Feb; 7(1):71-3. PubMed ID: 3132384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of antimicrobial resistance among respiratory tract isolates in Latin America: results from SENTRY antimicrobial surveillance program (1997-98).
    Sader HS; Gales AC; Granacher TD; Pfaller MA; Jones RN;
    Braz J Infect Dis; 2000 Oct; 4(5):245-54. PubMed ID: 11063556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1996)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Shimizu Y; Terai T; Inoue H; Nakadate T; Ito C; Yoshida T; Ohno I; Tanno Y; Arakawa M; Igarashi K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Nakata K; Nakatani T; Inagawa H; Kusano N
    Jpn J Antibiot; 1998 Jul; 51(7):437-74. PubMed ID: 9755430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1994)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Kobayashi K; Satou K; Matsumiya H; Saito A; Terai T; Tanno Y; Nishioka K; Arakawa M; Wada K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Matsuda M; Tanimoto H; Nakata K; Nakamori Y; Kusano N
    Jpn J Antibiot; 1996 May; 49(5):419-55. PubMed ID: 8752860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of the antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis. Canadian Antimicrobial Study Group.
    Blondeau JM; Suter M; Borsos S
    J Antimicrob Chemother; 1999 Mar; 43 Suppl A():25-30. PubMed ID: 10225568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicentre in-vitro evaluation of the susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis to ciprofloxacin, clarithromycin, co-amoxiclav and sparfloxacin.
    Hoogkamp-Korstanje JA; Dirks-Go SI; Kabel P; Manson WL; Stobberingh EE; Vreede RW; Davies BI
    J Antimicrob Chemother; 1997 Mar; 39(3):411-4. PubMed ID: 9096192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.